|1.||Nabid, Mohammad Reza: 2 articles (07/2014 - 11/2012)|
|2.||Niknejad, Hassan: 2 articles (07/2014 - 11/2012)|
|3.||de Oliveira, Mônica Cristina: 2 articles (01/2012 - 07/2011)|
|4.||de Barros, André Luís Branco: 2 articles (01/2012 - 07/2011)|
|5.||Soares, Daniel Crístian Ferreira: 2 articles (01/2012 - 07/2011)|
|6.||Ramaldes, Gilson Andrade: 2 articles (01/2012 - 07/2011)|
|7.||Cardoso, Valbert Nascimento: 2 articles (01/2012 - 07/2011)|
|8.||Yung, Lin Yue Lanry: 2 articles (07/2010 - 11/2009)|
|9.||Zhao, Haizheng: 2 articles (07/2010 - 11/2009)|
|10.||Huang, Hailong: 1 article (11/2015)|
06/01/2007 - "Moreover, it was possible to acquire the FR-targeted gamma images using PEG-folate conjugates in tumor models."
06/01/2007 - "On in vivo images, the tumor-to-normal muscle ratio was greater than 4. It ascertained that the PEG-folate conjugate specifically binds to the FR expressed on tumor cells in vitro. "
02/01/2004 - "In addition to a reduced tumor volume, LPD-PEG-Folate-TK treatment also increased median survival from 25 days in the nontargeted LPD-PEG-TK groups to 31 days (P=.0011), which correlated with the termination of treatment. "
07/01/2002 - "In an attempt to achieve extended circulation times and to target tumors by systemic delivery, we have coated the particles with PEG-folate residues. "
01/01/2014 - "Doxorubicin-conjugated PLA-PEG-Folate based polymeric micelle for tumor-targeted delivery: synthesis and in vitro evaluation."
|2.||Breast Neoplasms (Breast Cancer)
02/01/2004 - "In the current study, the antitumor efficacy of LPD-PEG-Folate in a syngeneic, immune competent, murine model of breast cancer was examined. "
02/01/2004 - "Previous studies from our group have demonstrated the antitumor efficacy of systemically administered, folate-targeted, lipid-protamine-DNA complexes (LPD-PEG-Folate) against breast cancer using an immunodeficient xenogenic murine model. "
02/01/2004 - "Moreover, in vivo treatment of 410.4 breast tumors in BALB/c mice with i.v. injected LPD-PEG-Folate delivering the HSV-1 thymidine kinase (TK) gene, in combination with gancyclovir treatment, resulted in a significant reduction in mean tumor volume (260.1 mm3) compared to the LPD-PEG-TK (914.1 mm3), as well as the vehicle (749.7 mm3) and untreated (825.3 mm3) control groups (day 25, P<.019). "
01/01/2013 - "Therefore, the PET tracer [18F]fluoro-PEG-folate was synthesized and evaluated in both in vitro and ex vivo studies using a methylated BSA induced arthritis model. "
01/01/2013 - "These results warrant further exploration of [18F]fluoro-PEG-folate as a putative PET tracer for imaging (sub)clinical arthritis in RA patients."
01/01/2013 - "The novel PET tracer [18F]fluoro-PEG-folate, designed to target FR on activated macrophages provided improved contrast in a rat model of arthritis compared with the accepted macrophage tracer (R)-[11C]PK11195. "
01/01/2013 - "Evaluation of the novel folate receptor ligand [18F]fluoro-PEG-folate for macrophage targeting in a rat model of arthritis."
02/01/2004 - "The 410.4 murine breast adenocarcinoma cell line was initially evaluated in vitro for its interactions with LPD-PEG-Folate and control LPD-PEG formulations. "
02/01/2004 - "In vivo efficacy of folate-targeted lipid-protamine-DNA (LPD-PEG-Folate) complexes in an immunocompetent syngeneic model for breast adenocarcinoma."
|1.||Folic Acid (Vitamin M)
|2.||DNA (Deoxyribonucleic Acid)
|5.||(R)- (11C)1- (2- chlorophenyl)- N- methyl- N- (1- methylpropyl)- 3- isoquinolinecarboxamide
|7.||Ethylene Glycol (Monoethylene Glycol)
|10.||Pentetic Acid (DTPA)